GXI.DE Gerresheimer AG XETRA pre-market €19.34 18 Mar 2026: earnings set to guide

We see GXI.DE stock trading at €19.34 pre-market on XETRA as Gerresheimer AG heads into its earnings release for 19 March 2026. The print will spotlight margins, working capital trends and cash flow after a sharp YTD decline of -30.43%. Investors will watch EPS of €0.68 and guidance for free cash flow while the market weighs high leverage and a PE of 28.44 against sector peers in Healthcare. We summarise what to expect, how the report ties to price, and key scenarios for traders and longer-term investors.

GXI.DE stock: earnings ahead and what to watch

Earnings on 19 March 2026 are the immediate catalyst for GXI.DE stock. We expect management to address near-term demand for pharma packaging, order backlog trends in Plastics & Devices, and margin recovery plans after operating income fell year-over-year. Key numbers to watch in the release are revenue growth, adjusted EBIT margin, and free cash flow. One clear market trigger will be commentary on net debt and working capital given enterprise value of €2,832.70m against market cap €668.00m.

Valuation and recent price action

Gerresheimer shares resumed buying pre-market after a recent bounce; the stock opened at €18.24 and is trading at €19.34 with volume above average at 403,130 shares. That follows a one-year slide of -75.89% from the 52-week high €80.80. On valuation the company shows a PE of 28.44 and a price-to-book of 0.48, reflecting heavy asset backing but stressed profitability. Compared with the Healthcare sector average PE 29.52, GXI.DE stock sits broadly in line on PE while carrying higher net leverage.

Profitability, cash flow and leverage

Gerresheimer reports EPS €0.68 and operating cash flow per share €7.34 but negative free cash flow per share -€2.51. Debt-to-equity stands at 1.65 and net debt to EBITDA is 5.48x, signalling material leverage risk if margins weaken. Interest coverage is low at 1.64x. For earnings, investors should focus on margin recovery and any CAPEX plans; capex per share is €18.48, which pressures free cash flow in the near term.

Balance sheet risks and opportunities

A tight current ratio of 0.98 and working capital of -€18.77m point to short-term liquidity strain in downside scenarios. Upside comes from scale in Primary Packaging Glass and growth in Advanced Technologies (smart drug delivery). Inventory days are elevated at 113.46 days, but revenue per share of €65.15 shows steady top-line support. Management commentary on order book and receivables will determine whether inventory and receivables convert into cash.

Technical setup and trading cues

Technically GXI.DE stock shows RSI 42.59, MACD histogram slightly positive, and ATR 1.46, suggesting higher intraday volatility into the print. Short-term averages are below the 50-day mean €22.63 and 200-day €33.38, so a beat plus constructive guidance would likely push the stock above the 50-day. Traders should watch the Bollinger middle band at €18.70 and a breakout above €21.88 for momentum confirmation.

Meyka AI grade and forecast model

Meyka AI rates GXI.DE with a score out of 100: 66.01 / B — HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics and analyst signals. Meyka AI’s forecast model projects a 12-month base-case target €24.00, a bear case €14.00, and a bull case €33.00. Compared with the current price €19.34, the base case implies upside of +24.07% and the bear case implies downside of -27.58%. Forecasts are model-based projections and not guarantees. For context, recent news and peer comparison are available from MarketWatch and competitor comparisons on Investing.com. Meyka AI provides this as an AI-powered market analysis platform for investors.

Final Thoughts

Gerresheimer (GXI.DE) arrives at earnings with the stock trading at €19.34 and clear short-term questions around cash conversion and leverage. The upcoming report should clarify whether margins and free cash flow can recover fast enough to justify a higher multiple. Our Meyka AI base-case target €24.00 implies +24.07% upside from today, while a downside case to €14.00 would be -27.58% if cash flow deterioration continues. The stock’s PE 28.44, negative free cash flow yield and net debt to EBITDA 5.48x create binary outcomes: a solid beat and constructive guidance could push shares above the 50-day average €22.63, while a weak print will likely reopen downside toward recent lows. We rate the equity as HOLD under the Meyka framework and advise watching the earnings release for working capital commentary, capex plans, and explicit guidance on leverage reduction. All forecasts are model-based projections and not guarantees; investors should use the earnings print to re-evaluate risk sizing and time horizons.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.